Founded in August 2002, Serum Life Science Europe GmbH (SLS Europe) – formerly Vakzine Projekt Management GmbH (VPM) – was established following an initiative of the German Federal Ministry of Education and Research (BMBF) to promote vaccine development within the country. With a funding support from BMBF between 2001 and 2010, our company organized and financed the preclinical and clinical development of vaccines nationwide. Our efforts involved identifying promising vaccine candidates from public German laboratories and overseeing their development until they were licensed to industrial partners. To ensure a solid foundation for our mission, we crafted a comprehensive map of vaccine research with the associated technologies at the beginning of the BMBF funding and updated in 2006.
Supporting Biopharmaceutical Development in Germany
Tailored Solutions and Consulting
Since 2008, we have expanded our services to offer tailor-made hands-on solutions and consultancy. Drawing from our extensive experience and a robust network of reliable partners, we serve small, medium, and large biopharmaceutical enterprises, private funding organizations, and research groups. Our consulting and service offerings span the entire product development value chain, as we have mastered each of these value points through our own endeavors.
Our Innovative Product Portfolio
Over the years, we have developed five products of our own, with a special focus on three main candidates:
VPM1002BC – Bladder Cancer Immunotherapeutic: Offering new hope for bladder cancer treatment.
VPM1002 – Novel Tuberculosis Vaccine Candidate: A promising and the most advanced clinical-stage vaccine in the fight against tuberculosis.
VPM2001 – CMV Vaccine: A significant step forward in tackling cytomegalovirus.
These products boast a combined target market of over 6 billion Euros and have been successfully out-licensed to pharmaceutical companies, alongside R&D contracts to further their development.
Proudly Partnered with Serum Institute of India (SIIPL)
Since July 2018, Serum Institute of India (SIIPL) is the majority shareholder of SLS Europe. We still operate as an independent entity and continue to provide services for our clients as before. SIIPL is the world’s largest vaccine manufacturer by number of doses produced and sold globally (more than 1.5 billion doses). SIIPL’s renowned vaccines, accredited by the World Health Organization, have been vital in national immunization programs across approximately 170 countries, saving millions of lives worldwide.
Embracing Advancement: VPM Becomes SLS Europe
In 2023, we embraced a significant change, officially changing our name from Vakzine Projekt Management (VPM to Serum Life Science Europe (SLS Europe). This name change signifies the company’s growth, development, and dedication to advancing biopharmaceutical innovations for a healthier world. With accumulated experience and knowledge in a broad range of service areas, we confidently stride into this new era.